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Abstract
Psoriasis is a chronic, immune-mediated, inflammatory, and 
debilitating skin disease with significant impact on patients’ 
quality of life. Its pathogenesis is complex and not yet fully 
understood. However, the IL-23/IL-17 axis is currently considered 
the main pathogenic pathway in psoriasis. Guselkumab is a fully 
human immunoglobulin G1 λ (IgG1λ) monoclonal antibody (mAb) 
that binds to the p19 subunit of IL-23. It is the first of its class, 
already approved by the US Food and Drug Administration (FDA), 
as well as the European Medicines Agency (EMA) for the treatment 
of adult patients with moderate-to-severe plaque psoriasis who 
are candidates for either systemic therapy or phototherapy. 
Several clinical trials have demonstrated potential benefits of 
guselkumab over other already approved immunomodulators in 
terms of safety and efficacy. The results of the head-to-head trial 
ECLIPSE were recently released and are addressed in this review. 
They contribute to the increasing confidence in guselkumab, 
demonstrating great potential for long-term treatment of 
psoriasis. However, further long-term data and additional 
comparative studies will be essential for positioning guselkumab 
in the therapeutic armamentarium for psoriasis.
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Introduction
Psoriasis is a chronic, immune-mediated, inflammatory skin 
disease that affects over 125 million people worldwide,1–3 
with significant impact on patients’ quality of life.4 Due to its 
systemic nature, psoriasis is associated with several medical 
comorbidities, including cardiovascular disease, inflammatory 
bowel disease, and psychiatric diseases.5–9 
Psoriasis pathogenesis is complex and not yet fully understood. 
Even though, disease knowledge has significantly evolved in 
past years leading to the development of increasingly specific 
and efficacious targeted therapies.10–13 
During the initiation phase of the psoriatic skin lesions, an 
increment of the production of TNF occurs and, as a result, 
activation of dermal dendritic cells.14,15 These cells are 
responsible for the increased production of IL-23 and the 
subsequent activation of distinct subgroups of IL-17 producing 
cells (T17) (helper T cells [Th17]; cytotoxic T cells [Tc17]; innate 
lymphoid cells [ILC3]; and γδ T cells).14,16–18 As IL-23 levels rise, 
secreted mainly from inflammatory dermal dendritic cells, T17 
cells increase in number and produce large amounts of IL-17, 
specifically isoforms IL-17A and F, which drive the upregulation 
of many psoriasis-related genes.14,19 The clonal expansion of 
T17 cells and subsequent increased levels of IL-17 feedforward 
an inflammatory response and lead to keratinocyte 
hyperproliferation.14,15,20,21 Other types of cells, such as 
dermal macrophages and epidermal keratinocytes, were also 
associated with the increased production of IL-23 and may 
contribute to psoriatic lesions’ installation and maintenance.14,22 
The discovery of the IL-23/IL-17 axis, widely considered the most 
critical pathogenic pathway on the development of psoriasis, 
and the development of drugs targeting this pathway shifted 
the paradigm of the management of this condition.15,20,23
The development of IL-17 inhibitors showed that the blockade 
of the pathway of this cytokine was associated with high levels 
of efficacy and rapid onset of action in moderate-to-severe 
psoriasis, but also better clinical responses than either TNF-α 
inhibitors or ustekinumab, a nonselective IL-23 inhibitor.24–31 
However, several side effects such as neutropenia, candidiasis, 
and exacerbations of Crohn’s disease have been associated with 
these agents,24–31 reinforcing the need for new therapeutic 
solutions. More recently, selective IL-23 inhibitors such as 
guselkumab, tildrakizumab, and risankizumab have emerged, 
showing a very effective, durable, and safe profile32–40
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This article intends to review the current literature on 
guselkumab in the management of psoriasis.
Guselkumab pharmacology 
Guselkumab® (Janssen Biotech, Inc., Horsham, PA, USA) 
is a fully human immunoglobulin G1 λ (IgG1λ) monoclonal 
antibody (mAb) that binds to the p19 subunit of IL-23. It is 
first of its class to be approved by the US Food and Drug 
Administration (FDA)41 as well as the European Medicines 
Agency (EMA)42,43 for the treatment of adult patients with 
moderate-to-severe plaque psoriasis who are candidates for 
either systemic therapy or phototherapy. In light of its clinical 
efficacy in plaque psoriasis, guselkumab has also been or is 
currently being evaluated for the treatment of other diseases, 
namely generalized pustular psoriasis (GPP), erythrodermic 
psoriasis (EP), psoriatic arthritis, rheumatoid arthritis, and 
Crohn’s disease.
Pharmacodynamic properties
Guselkumab binds with both high affinity and high specificity 
to IL-23,43 preventing the interaction of the cytokine with its 
receptor on the surface of the cell. This action is responsible 
for blocking the initiation of the IL-23 pathway and the 
subsequent release of other proinflammatory cytokines 
(Figure 1). 
In patients with moderate-to-severe plaque psoriasis, the 
biopsy of skin samples from body regions affected with the 
disease, compared to nonlesional regions, before and after a 
single dose of guselkumab, showed that the drug is responsible 
for a significant (p<0.05) reduction in inflammatory dendritic 
cell and T-cell counts, and epidermal thickness at week 12 
compared to baseline.32 Significant reductions in IL-17A 
serum levels since week 1 were observed when compared 
to baseline values (versus no change in placebo recipients) 
in patients considered as responders to guselkumab (with 
≥50% improvement in the Psoriasis Area and Severity Index 
score [PASI 50] measured at week 12), with a response that was 
dose-dependent.32 Guselkumab has also shown a substantial 
impact in both the reduction of mRNA expression of IL-17F 
and IL-22, as well as in increased levels of INF-γ, produced 
by T-helper 1 (Th1) cells, thus proposing that the drug’s 
clinical performance relies primarily in the inhibition of the  
IL-23/Th17 pathway, allowing the IL-12/Th1 axis to remain 
intact32 (Figure 1).
Pharmacokinetic properties
Zhuang and colleagues37 conducted a first-in-human, 
phase I, randomized trial to assess the pharmacokinetics, 
immunogenicity, safety, and tolerability of guselkumab 
following a single intravenous (IV; 0.03–10 mg/kg) or 
subcutaneous (SC; 10–300 mg) administration in healthy 
subjects and patients with moderate-to-severe psoriasis. 
The pharmacokinetic profile of guselkumab was generally 
comparable between healthy subjects and patients 
with psoriasis. Investigators also noted that there was a 
Figure 1. The IL-12 and IL-23 heterodimers are each composed of a common p40 subunit and a unique p35 and  
p19 subunit, respectively. The nonselective IL-23 inhibitors, such as ustekinumab, bind to the p40 
subunit on IL-12 and IL-23, thereby inhibiting both signalling pathways. The selective IL-23 inhibitors, 
as guselkumab, bind to the p19 subunit on IL-23 and inhibit only the IL-23-mediated signalling pathway, 
allowing the IL-12 axis to remain intact.
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IGA score of 0/1, PASI 75, and PASI 90 responses at weeks 16, 24, 
and 48, respectively. A fixed sequence method of analyses was 
used to control the overall type 1 error rate. 
At week 16, comparing to the placebo group, a significantly 
higher proportion of patients receiving guselkumab had 
achieved an IGA score of 0/1 (85.1 versus 6.9%) and PASI 90 
(73.3 versus 2.9%) response. In addition, a significantly higher 
proportion of patients achieving IGA 0, PASI 75, and PASI 
100 was observed in guselkumab group versus the placebo 
group (Table 2).34 When compared to adalimumab at week 
16, guselkumab was statistically superior, as observed by the 
percentage of patients achieving an IGA score of 0/1 (85.1 versus 
65.9%), PASI 75 (91.2 versus 73.1%), and PASI 90 (73.3 versus 
49.7%) responses. These responses maintained significance 
throughout week 24 (IGA 0/1 [84.2 versus 61.7%], PASI 75 [91.2 
versus 72.2%], and PASI 90 [80.2 versus 53.0%]) and week 48 (IGA 
0/1 [80.5 versus 55.4%], PASI 75 [87.8 versus 62.6%], and PASI 90 
[76.3 versus 47.9%]). Similarly, the proportion of patients who 
achieved a PASI 100 response in the guselkumab group was 
significantly higher than in the adalimumab group at every 
checkpoint (weeks 16 [37.4 versus 17.1%], 24 [44.4 versus 24.9%], 
and 48 [47.4 versus 23.4%]). With the initiation of guselkumab 
at week 16, patients in the placebo crossover group achieved 
similar responses to those receiving guselkumab since week 
0.34 Guselkumab was proven superior to both the placebo and/
or adalimumab in the attainment of the coprimary endpoints 
and all major secondary endpoints (all p<0.001) in this clinical 
trial.34 For a more detailed analysis of the results, see Table 2. 
Regional psoriasis was also evaluated and analysed in this 
trial. For this purpose, investigators used scores such as scalp-
specific IGA (ss-IGA), Nail Psoriasis Severity Index (NAPSI), 
fingernail Physician’s Global Assessment (PGA) (f-PGA), and 
PGA of the hands and/or feet (hf-PGA). A significantly greater 
proportion of patients treated with guselkumab reached an 
ss-IGA score of 0/1 compared with placebo at week 16 (83.4 
versus 14.5%; p<0.001). Using the same score, guselkumab also 
showed significantly higher efficacy than adalimumab at weeks 
24 (84.5% in guselkumab group versus 69.2% in adalimumab 
group) and 48 (78.3% in guselkumab group versus 60.5% in 
adalimumab group) (both p<0.001).34 Compared to placebo at 
week 16, the guselkumab group had a higher mean per cent 
improvement in the NAPSI score and a greater proportion 
of patients achieving an f-PGA score of 0/1. Compared to 
adalimumab, the results in the f-PGA score were similar at 
week 24 but significant differences were observed at week 
48 in patients treated with guselkumab (p=0.038).34 There 
were no differences between guselkumab and adalimumab 
groups concerning the NAPSI score, measured at weeks 24 and 
48.34 A higher percentage of patients receiving guselkumab, 
comparing to those receiving placebo, achieved the hf-PGA 
score of 0/1 at week 16 (73.3 versus 14.0%; p<0.001). Regarding 
to the same score, guselkumab-treated patients also had better 
responses when compared to adalimumab-treated patients at 
week 24 (78.9 versus 56.8%; p<0.001) and week 48 (75.6 versus 
62.1%; p<0.045).34
dose-dependent increase in the mean maximum serum 
concentration and area under the zero-to-infinity serum 
concentration–time curve.37
Yao and colleagues44 established a population 
pharmacokinetics model using the information from three 
clinical trials involving guselkumab: the phase II X-PLORE 
(NCT01483599) and two phase III trials, namely VOYAGE 
1 (NCT02207231) and VOYAGE 2 (NCT02207244). The final 
model showed an apparent clearance and apparent volume 
of distribution of 0.516 L/day, and 13.5 L, respectively. Mean 
half-life time values were consistent between both healthy 
subjects (12–19 days) and patients with psoriasis (15–17 days). 
The model-derived elimination half-life of the drug allowed 
for the conclusion that steady-state serum guselkumab 
concentrations occurred between weeks 12 and 14.44 However, 
Smolen and colleagues45 reported that the median serum 
levels of guselkumab would only reach the steady state by 
week 20, which is the information provided by EMA about the 
product.43
Therapeutic efficacy of 
guselkumab in psoriasis
Large, randomized, multinational, phase III trials (VOYAGE 
1, VOYAGE 2, NAVIGATE [NCT02203032], and ECLIPSE 
[NCT03090100]) assessed the clinical efficacy of subcutaneous 
guselkumab in the treatment of moderate-to-severe plaque 
psoriasis in adults. Results from other trials support this data 
and will not be discussed further.33,46 
Patients enrolled in the previously reported phase III clinical 
trials were individuals with ≥18 years of agewith moderate-
to-severe plaque psoriasis for at least 6 months and had to 
be eligible for systemic therapy or phototherapy. Patients 
in VOYAGE trials and NAVIGATE had an initial Investigator 
Global Assessment (IGA) score of 3 or more, a minimum 
affected body surface area (BSA) of ≥10%, and a PASI score 
of 12 or more. These studies excluded patients with history 
or symptoms of active tuberculosis, other types of psoriasis 
(guttate, erythrodermic, or pustular), or who had been exposed 
to guselkumab or the active comparator (adalimumab in 
VOYAGE trials; ustekinumab in NAVIGATE; and secukinumab in 
ECLIPSE).34–36,38
VOYAGE trials
VOYAGE 1 was a phase III randomized, double-blind trial, 
which evaluated the effectiveness of guselkumab compared 
to placebo and adalimumab.34 For study design, see Table 1. 
The proportion of patients with an IGA score of 0/1 (cleared/
minimal disease) and the proportion of patients with an at 
least PASI 90 response, both at week 16, were used to evaluate 
the clinical efficacy of guselkumab compared to placebo (as 
coprimary endpoints). To assess the efficacy of guselkumab 
compared to that of adalimumab, investigators used as major 
secondary endpoints the proportion of patients achieving an 
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Health-related quality of life (HRQoL) was also evaluated with 
patient-reported outcomes using the Psoriasis Symptoms 
and Signs Diary (PSSD) and the Dermatology Life Quality 
Index (DLQI). Mean changes in the PSSD score from baseline 
for guselkumab-treated patients were higher than placebo 
at week 16 and higher than adalimumab at weeks 24 and 48 
(p<0.001 for all three). It was possible to observe a significantly 
higher improvement from baseline DLQI in the group of 
patients who received guselkumab compared with placebo 
(−11.2±7.2 versus −0.6±6.4; p<0.001), with a concomitant higher 
proportion of patients achieving the DLQI score of 0/1 (56.3 
versus 4.2%; p<0.001) at week 16. The investigators noted 
that guselkumab also outperformed adalimumab concerning 
both improvements from the baseline DLQI score (week 24 
[−11.6±7.6 versus −9.5±7.9; p<0.001] and week 48 [−11.8±7.9 
versus −9.2±8.3; p<0.001]) and achievement of the DLQI score 
of 0/1 (week 24 [60.9 versus 39.5%; p<0.001] and week 48 [62.5 
versus 38.9%; p<0.001]).34
Still in VOYAGE 1, an open-label extension period began where 
patients who were having guselkumab as treatment agreed to 
continue to receive the drug every 8 weeks, whereas patients 
in the adalimumab group accepted to change to guselkumab 
at week 52 and every 8 weeks thereafter, after taking their last 
dose of adalimumab at week 47. At week 100, the proportion of 
patients who achieved an IGA score of 0/1, the IGA score of 0, 
PASI 75, PASI 90, and PASI 100 responses were 82.4, 53.8, 94.8, 
82.1, and 49.0%, respectively. Placebo–guselkumab crossover 
and adalimumab–guselkumab crossover groups achieved 
similar results at week 100. It was concluded that efficacy 
was maintained through 2 years amongst patients who had 
continued treatment with guselkumab, and patients who 
changed from adalimumab to guselkumab after 1 year had 
improved efficacy at 2 years.47
In VOYAGE 2 trial, investigators assessed the efficacy and safety 
of guselkumab in moderate-to-severe psoriasis versus both 
Table 1. Study design for each phase III trials.
Clinical trial Number of 
patients
Study design
VOYAGE 1 837 Patients were randomized in a 1:2:2 ratio for one of three scenarios: 
(1)  Placebo (weeks 0, 4, and 12), followed by guselkumab (100 mg; weeks 16, 20, and 
every 8 weeks through week 44) (n=174);
(2) Guselkumab (100 mg; weeks 0, 4, and every 8 weeks through week 44) (n=329);
(3)  Adalimumab (80 mg at week 0, 40 mg at week 1, and 40 mg every 2 weeks 
through week 47) (n=334).
VOYAGE 2 992 Patients were randomized in a 2:1:1 ratio to:
(1) Guselkumab (100 mg; weeks 0, 4, 12, and 20) (n=496); 
(2)  Placebo (weeks 0, 4, and 12), and then receive guselkumab (100 mg; weeks 16 and 
20) (n=248) – placebo–guselkumab crossover group;
(3)  Adalimumab (80 mg at week 0, then 40 mg at week 1, and every 2 weeks through 
week 23) (n=248) 
At week 28, the patients treated with guselkumab with PASI 90, considered as responders, 
were rerandomized in a 1:1 ratio to guselkumab or placebo, with guselkumab after loss of 
response (loss of 50% or more of week-28 PASI response). Placebo–guselkumab crossover 
responders and adalimumab responders received placebo, then guselkumab after loss 
of response. Nonresponders received guselkumab. Patients received either placebo or 
guselkumab through week 72.
NAVIGATE 871 Patients received open-label ustekinumab (45 mg for patients ≤100 kg, 90 mg for patients 
>100 kg) at weeks 0 and 4. At week 16, 268 patients with an inadequate response to 
ustekinumab, considered as an IGA score of 2 or more, were randomized (double-blind) to:
(1)  Guselkumab (100 mg; weeks 16, 20, and every 8 weeks thereafter through week 
44) (n=135); 
(2)  Continue ustekinumab (week 16 and every 12 weeks after that through week 40) 
(n=133).
ECLIPSE 1048 Participants received one injection of active guselkumab and one injection of placebo 
when guselkumab was scheduled to be administered (weeks 0, 4, 12, and every 8 weeks 
thereafter through week 44) or two injections of placebo when no guselkumab was 
scheduled to be administered (weeks 1, 2, 3, 8, 16, 24, 32, and 40). Placebo injections were 
administered to maintain the blind. 
On the other hand, participants received two injections of secukinumab subcutaneously at 
weeks 0, 1, 2, 3, 4, and every 4 weeks thereafter through week 44.
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placebo and adalimumab, including in the study one arm with 
discontinuation of guselkumab and another with switching 
adalimumab nonresponders to guselkumab35 (Table 1).
At week 16, comparing to the placebo group, a higher number 
of patients receiving guselkumab achieved an IGA score of 
0/1 (84.1 versus 8.5%) and PASI 90 (70.0 versus 2.4%) response 
(coprimary endpoints) (both p<0.001). Guselkumab was also 
superior to adalimumab at weeks 16 and 24, as measured by 
the proportion of patients achieving an IGA score of 0/1 (week 
16 [84.1 versus 67.7%] and week 24 [83.5 versus 64.9%]), PASI 75 
(week 16 [86.3 versus 68.5%] and week 24 [89.1 versus 71.0%]), 
PASI 90 (week 16 [70.0 versus 46.8%] and week 24 [75.2 versus 
54.8%]), and PASI 100 (week 16 [34.1 versus 20.6%] and week 24 
[44.2 versus 26.6%]) responses (all p<0.001). From weeks 28 to 
48, a higher persistence of response (PASI≥90) was observed 
in the guselkumab maintenance group versus the withdrawal 
group (88.6 versus 36.8%; p<0.001). For withdrawal patients, 
the median time to loss of PASI 90 response was 15.2 weeks.35 
Regarding the group of patients considered as nonresponders 
to adalimumab who switched to guselkumab, 66.1% achieved 
PASI 90 at week 48, and 28.6% achieved PASI 100. Guselkumab 
Table 2. Summary of key results from clinical trials with guselkumab.
Clinical trial Proportion of patients achieving
PASI 75 PASI 90 PASI 100 IGA 0/1 DLQI 0/1
VOYAGE 1 At wk 16:
Gus 91.2%;  
ADA 73.1%;  
PL 5.7%
At wk 16:
GUS 73.3%;  
ADA 49.7%;  
PL 2.9%
At wk 16:
GUS 37.4%;  
ADA 17.1%;  
PL 0.6%
At wk 16:
GUS 85.1%;  
ADA 65.9%;  
PL 6.9%
At wk 16:
GUS 56.3%;  
ADA 38.6%;  
PL 4.2%
At wk 24:
GUS 91.2%;  
ADA 72.2%
At wk 24:
GUS 80.2%;  
ADA 53.0%
At wk 24:
GUS 44.4%;  
ADA 24.9%
At wk 24:
GUS 84.2%;  
ADA 61.7%
At wk 24:
GUS 60.9%;  
ADA 39.5%
At wk 48:
GUS 87.8%;  
ADA 62.6%
At wk 48:
GUS 76.3%;  
ADA 47.9%
At wk 48:
GUS 47.4%;  
ADA 23.4%
At wk 48:
GUS 80.5%;  
ADA 55.4%
At wk 48:
GUS 62.5%;  
ADA 38.9%
(all p<0.001) (all p<0.001) (all p<0.001) (all p<0.001) (all p<0.001)
VOYAGE 2 At wk 16:
GUS 86.3%;  
ADA 68.5%;  
PL 8.1%
At wk 16:
GUS 70.0%;  
ADA 46.8%;  
PL 2.4%
At wk 16:
GUS 34.1%;  
ADA 20.6%;  
PL 0.8%
At wk 16:
GUS 84.1%;  
ADA 67.7%;  
PL 8.5%
At wk 16:
GUS 51.7%;  
ADA 39.0%;  
PL 3.3%
At wk 24: 
GUS 89.1%;  
ADA 71.0%
At wk 24:
GUS 75.2%;  
ADA 54.8%
At wk 24:
GUS 44.2%;  
ADA 26.6%
At wk 24:
GUS 83.5%;  
ADA 64.9%
At wk 24:
GUS 57.6%;  
ADA 41.1%
(all p<0.001) (all p<0.001) (all p<0.001) (all p<0.001) (all p<0.001)
NAVIGATE NR At wk 28:
GUS 48.1%;  
UST 22.6%
At wk 28: 
NR
At wk 28: 
GUS 31.1%;  
UST 14.3%
At wk 28: 
NR
(p<0.001) (p=0.001)
At wk 52: 
GUS 51.1%;  
UST 24.1%
At wk 52:
GUS 20.0%;  
UST 7.5%
At wk 52: 
GUS 36.3%;  
UST 17.3%
At wk 52:
GUS 38.8%;  
UST 19.0%
(p<0.001) (p=0.003) (p<0.001)
ECLIPSE At wk 12:
GUS: 89.3%;  
SEC 91.6%
At wk 12:
GUS 69.1%;  
SEC 76.1%
At wk 12:
NR
At wk 12:
NR
NR
At wk 48:
NR
At wk 48:
GUS 84.5%;  
SEC 70.0%
At wk 48: 
GUS 58.2%;  
SEC 48.4%
At wk 48: 
GUS 85.0%;  
SEC 74.9%
(p<0.001)
Nonresponder imputation was used to assess binary endpoint missing data. All comparisons were made with guselkumab, and 
p-value represents the significance value of this comparison.
ADA, adalimuma; GUS, guselkumab; NR, not reported; PL, placebo; SEC, secukinumab; UST, ustekinumab; wk, week(s).
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improved patient-reported outcomes (DLQI and PSSD), similar 
to what was already demonstrated in VOYAGE 1.35 For a more 
detailed analysis of the results, consult Table 2. The efficacy 
of guselkumab versus both placebo and adalimumab was 
confirmed in VOYAGE 2 trial, because the results were similar to 
those observed in VOYAGE 1.35
Gordon and colleagues48 evaluated the consistency of 
guselkumab’s efficacy across several subpopulations of 
patients with psoriasis (defined by baseline demographics, 
disease characteristics, and previous exposure to treatments) 
using pooled information from VOYAGE 1 and VOYAGE 2 trials. 
Guselkumab provided significant benefit across almost all 
subpopulations, showing a more consistent response amongst 
lighter and heavier patients when comparing to adalimumab.48
NAVIGATE
NAVIGATE was a phase III, randomized, double-blind trial that 
assessed the clinical efficacy of guselkumab in patients with 
moderate-to-severe psoriasis who had a poor response to 
ustekinumab.36 For study design, consult Table 1. Amongst 
the initial 871 patients, 585 (67%) with an IGA score of 0/1 at 
week 16 continued to receive open-label ustekinumab.36 The 
investigators defined the number of visits in which randomized 
patients achieved an IGA score of 0/1 and at least a two-grade 
improvement in the IGA score (comparing to the IGA score 
at week 16) from week 28 through week 40 as the primary 
endpoint.36
The number of visits in which randomized patients achieved IGA 
of 0/1 was significantly higher in the group of patients receiving 
guselkumab versus the group receiving ustekinumab (1.5±1.6 
versus 0.7±1.3; p≤0.001).36 Langley and colleagues36 also observed 
that a higher proportion of patients treated with guselkumab 
achieved an IGA score of 0/1 with an at least two-grade 
improvement at weeks 28 (31.1 versus 14.3%; p=0.001) and 52 
(36.3 versus 17.3%; p<0.001). Investigators also noted that a greater 
proportion of patients treated with guselkumab, comparing to 
those receiving ustekinumab, achieved PASI 90 (51.1 versus 24.1%) 
and PASI 100 (20.0 versus 7.5%) responses (both p<0.005), as well 
as the DLQI score of 0/1 (38.8 versus 19.0%) at week 52.36 For a 
more detailed analysis of the results, see Table 2. This clinical 
trial gave us the opportunity to conclude that patients treated 
with ustekinumab who had a poor response at week 16 derived 
significant benefit from switching to guselkumab.36
ECLIPSE
A phase III randomized, double-blind, head-to-head trial called 
ECLIPSE was designed to assess guselkumab’s efficacy and 
safety compared to secukinumab in patients with moderate-to-
severe plaque psoriasis. For study design, consult Table 1.
The study demonstrated that guselkumab was superior to 
secukinumab for the primary endpoint assessed at week 48; 
that is, achievement of at least PASI 90 response (84.5% with 
guselkumab versus 70.0% with secukinumab; p<0.001).38 For a 
more detailed analysis of the results, see Table 2.
ECLIPSE incorporated six secondary endpoints evaluated 
at weeks 12 and 48. Investigators used a fixed statistical 
sequence procedure to control for multiple comparisons. At 
both weeks 12 and 48, 84.6% of patients receiving guselkumab 
achieved a PASI 75 response (versus 80.2% in the secukinumab 
group), demonstrating that guselkumab was not inferior to 
secukinumab in the first major secondary endpoint (p<0.001). 
However, it failed to demonstrate superiority and, with this 
in mind, p-values for all the subsequent major secondary 
endpoints were considered nominal.38 
Another three major secondary endpoints were evaluated at 
week 48. Compared to secukinumab, a higher proportion of 
patients in guselkumab group achieved an IGA score of 0/1 
(85.0 versus 74.9%), IGA of 0 (62.2 versus 50.4%), and PASI 100 
(58.2 versus 48.4%) response.38 
The remaining major secondary endpoints were assessed at 
week 12. Moreover, 89.3% of patients receiving guselkumab 
achieved a PASI 75 response, against 91.6% of patients receiving 
secukinumab. The proportion of patients achieving a PASI 90 
response was 69.1% for guselkumab and 76.1% for secukinumab.38
Safety and tolerability 
of guselkumab
Guselkumab was generally well tolerated in adults with 
moderate-to-severe plaque psoriasis in all pivotal trials.34–36,38 
Data from other phase I, II, and III trials support this 
information32,33,46 and will not be discussed further.
In VOYAGE 1, investigators reported comparable adverse events 
(AEs) amongst patients in the different treatment groups. 
Nasopharyngitis and upper respiratory tract infection were the 
most common adverse events reported.34 In addition to the 
fact that serious AEs and AEs leading to the discontinuation of 
the agent were uncommon, these events occurred in similar 
proportions for each treatment group throughout the study. 
Overall infections and infections requiring antibiotic treatment 
occurred at comparable rates across all treatment groups 
through week 48.34 By week 16, two major adverse cardiac 
events (MACEs) occurred, one in each of the guselkumab and 
adalimumab groups, and one patient receiving guselkumab 
developed a basal cell carcinoma. Between weeks 16 and 
48, four cases of serious infections were reported: two in the 
group of patients receiving guselkumab (one thigh abscess 
and one cellulitis with postoperative wound infection) and 
two in the group of patients receiving adalimumab (one 
abdominal abscess and one fatal staphylococcal pneumonia). 
Two malignancies (breast and prostate cancers), both in the 
guselkumab group, and two basal cell carcinomas, one in each 
of the guselkumab and adalimumab groups, were observed 
up to week 48. No additional MACEs were reported after week 
16. There were no differences between groups in the incidence 
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of neutropenia and candidiasis, which was low in all treatment 
groups. There were no differences between groups regarding 
the incidence of laboratory abnormalities, which was also low. 
No Crohn’s disease-related events were reported.34
VOYAGE 2 corroborated the safety data observed in VOYAGE 1  
regarding the comparable proportion of patients with one 
or more AE, AEs leading to discontinuation, and serious AEs 
in placebo and guselkumab groups through week 16.35 The 
most commonly reported events during placebo-controlled 
period (weeks 0–16) were nasopharyngitis, headache, and 
upper respiratory tract infection. That was the same pattern of 
AEs that were observed during the active-comparator period 
(weeks 0–28). No malignancies or nonmelanoma skin cancers 
(NMSCs) were reported through week 16. One MACE, specifically 
a myocardial infarction, occurred in the group of patients 
receiving the active-comparator adalimumab during placebo-
controlled period. A higher proportion of patients treated with 
adalimumab had Injection site reactions (ISR) (6.9 versus 2.6%).35 
Concerning to the active-comparator period, three serious 
infections were observed in each of the active treatment groups 
(guselkumab group: bronchitis, erysipelas, and soft tissue 
infection; adalimumab group: two cases of tuberculosis and 
one injection-site abscess). One malignancy (prostate cancer) 
and two NMSCs (one squamous cell carcinoma in the group of 
patients receiving guselkumab and one basal cell carcinoma in 
the placebo–guselkumab crossover group) were also reported. 
One patient in each of guselkumab- and adalimumab-treated 
groups developed a MACE through week 28.35 From weeks 28 
to 48, one serious infection was reported in the maintenance 
group (appendicitis). During this randomized withdrawal 
and retreatment period (weeks 28–48), one case of MACE 
was reported in the placebo–guselkumab crossover group. 
One additional basal cell carcinoma and one squamous cell 
carcinoma were noted in the same placebo–guselkumab group 
through week 48. Similar to what was observed in VOYAGE 1 
results, the incidence of laboratory abnormalities was low and 
comparable between groups.35
No new signs that would endanger the safety of the drug were 
identified during the long-term treatment (through 100 weeks) 
with open-label extension with guselkumab in VOYAGE 1 and 
VOYAGE 2.49
NAVIGATE brought no new safety data regarding patients 
who switched from ustekinumab to guselkumab without a 
washout period. Moreover, 64.0% of patients randomized to 
guselkumab had one or more AEs (versus 56.0% in ustekinumab 
group). Serious AEs were reported in 7% of patients treated 
with guselkumab (versus 5% with ustekinumab), and 2% of each 
group discontinued treatment due to an AE.36 
In the ECLIPSE trial, the safety profiles observed for both drugs 
(guselkumab and secukinumab) were consistent with the 
information already presented in the respective registration 
trials. Similar percentage of patients reported at least one 
AE (77.9% with guselkumab versus 81.6% with secukinumab). 
Serious AEs were reported in 6.2% of patients receiving 
guselkumab (versus 7.2% of patients receiving secukinumab). 
Investigators documented six serious infections in guselkumab-
treated patients (versus five in the secukinumab group).38
Immunogenicity
Zhuang and colleagues37 reported that 1 out of 20 (5.0%) patients 
in the second part of the phase I trial (which included patients 
with psoriasis) had positive antibodies to guselkumab. The 
incidence of antibodies to guselkumab reported in X-PLORE was 
6.0%.33 However, they were nonneutralizing and had low titres.33 
VOYAGE 1, VOYAGE 2, and NAVIGATE reported rates of antibody 
development of 5.3% through week 44, 6.6% through week 48, 
and 9.0% through week 60, respectively. No association between 
antibody incidence and reduced efficacy was noted.34–36
Other indications
A phase III, single‐arm, open‐label, multicentre trial conducted 
in Japan with 21 patients demonstrated the clinical benefit of 
using guselkumab in the treatment of other types of psoriasis, 
such as GPP and EP.50 Its efficacy was verified throughout the 
study period (52 weeks), and the safety profile of guselkumab 
was consistent with data already published in psoriasis. Sano 
and colleagues50 concluded that there would be a favourable 
risk–benefit profile for treating both GPP and EP patients with 
the selective IL-23 inhibitor. Nevertheless, further studies are 
required to confirm this effectiveness.
In a phase II randomized, double-blind, placebo-controlled 
trial, guselkumab demonstrated significant improvement in 
joints’ symptoms, physical function, enthesitis, dactylitis, and 
quality of life in patients with psoriatic arthritis.51 Two phase 
III trials are now underway to ascertain the efficacy and safety 
of guselkumab in patients who suffer from this pathological 
condition, either biologic-naive (NCT03158285) or previously 
treated with TNF-α inhibitors (NCT03162796).
Smolen and colleagues45 conducted a phase II trial that evaluated 
the safety and efficacy of guselkumab in patients suffering 
from active rheumatoid arthritis despite concomitant treatment 
with methotrexate. No statistically significant differences in the 
percentage of patients who achieved an American College of 
Rheumatology (ACR)-20 response between those who received 
guselkumab and the control group were found.45
To date, no published studies demonstrate the impact of 
guselkumab in the treatment of Crohn’s disease. However, 
ustekinumab, as a nonselective IL-23 inhibitor, has been shown 
to be effective treating this disease.52,53 Currently, a clinical trial 
is ongoing (GALAXI [NCT03466411]), and is recruiting patients 
and pretends to evaluate the efficacy and safety of guselkumab 
in participants with Crohn’s disease.
Discussion
As previously mentioned, the discovery of the IL-23/IL-17 axis 
has led to a substantial increase in our knowledge of the 
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pathogenic immune events present in psoriasis and to shift the 
paradigm of the management of this condition. IL-17 inhibitors 
were approved previously than IL-23 selective inhibitors for the 
treatment of moderate-to-severe psoriasis. However, several 
complications have been associated with these agents, raising 
the need for different therapeutic solutions. 
Although the inhibition of IL-23 alone rather the coinhibition 
of both IL-23 and IL-12 presents as a novel mechanism of 
action, the favourable safety profile of guselkumab has not 
come as a surprise, because long-term data were available for 
ustekinumab.53,54 However, allowing the IL-12/Th1 axis to remain 
intact, as is the case with guselkumab, may be a net-positive 
effect because the cytokines involved in this pathway contribute 
vitally to the hosts’ defence through their ability to stimulate both 
innate and adaptive immune effector cells against intracellular 
microbial infection and malignant cells.55–57 These cytokines also 
allow the initiation of a protective transcriptional program in 
keratinocytes that will limit skin inflammation mediated by T17 
cells.15,58 Treatment with an IL-23p19 inhibitor led to long-term 
responses in some patients with just a single dose32 or after a 
withdrawal after 28 weeks of contact with the drug (in VOYAGE 2, 
36.8% of patients rerandomized to placebo sustained PASI 90 at 
week 48).35 This clinical response can be explained in part by the 
impact of IL-12 in promoting transdifferentiation of Th17 cells into 
regulatory T cell or Th1 populations.15,59
Although IL-23 and IL-39 (another proinflammatory cytokine 
likely expressed in psoriatic skin) share the p19 subunit, 
whether guselkumab can bind to or inhibit human IL-39 is 
unknown, and further studies are required to explore the 
individual role of this cytokine.20
Several reviews have been published regarding the role of 
guselkumab in the treatment of psoriasis.60–63 However, 
recent divulgation of the results of ECLIPSE reinforces the 
role of the selective IL-23 inhibitor concerning other already 
approved immunomodulators, such as the active-comparator 
secukinumab used in trial.38 Even though secukinumab 
achieved a slightly faster onset of response, detailed analysis 
with the response-over-time curves showed that maximum 
response rates with guselkumab are achieved later – after 
6 months – and are maintained over time through 1 year, 
translating into superiority for the primary endpoint of the 
study (PASI 90 response).38 The superiority of guselkumab 
in comparison to secukinumab is also apparent in the less 
frequent dosing regimen of the selective IL-23 inhibitor 
(guselkumab: initially at weeks 0 and 4, but then every 8 weeks 
versus secukinumab: administered weekly for 4 weeks followed 
by every 4 weeks as a maintenance dosing). From the patients’ 
point of view, characteristics such as less frequent drug 
administration or the option of self-administration contribute 
to better adherence and thus better clinical outcomes.
Conclusion
Guselkumab is a monoclonal antibody that selectively targets 
IL-23, and it is the first in its class to be approved to treat 
moderate-to-severe plaque psoriasis. Its efficacy and safety 
profiles were reinforced by recent studies such as ECLIPSE, 
demonstrating great potential for long-term treatment of 
psoriasis. Long-term data and additional comparative studies 
will be essential for positioning guselkumab in the therapeutic 
armamentarium for psoriasis.
Contributions: Both authors contributed equally to the preparation of this review. The named authors meet the International Committee of 
Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given 
their approval for this version to be published.
Disclosure and potential conflicts of interest: Miguel Nogueira has no conflicts of interest. Tiago Torres is a scientific consultant/
speaker/clinical study investigator for AbbVie, Amgen, Boehringer Ingelheim, Biogen, Celgene, Janssen, LEO-Pharma, Eli-Lilly, MSD, Novartis, 
Pfizer, Samsung Bioepis, Sanofi. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the 
authors is available for download at http://www.drugsincontext.com/wp-content/uploads/2019/06/dic.212594-COI.pdf
Acknowledgements: None. 
Funding declaration: There was no funding associated with the preparation of this article.
Copyright: Copyright © 2019. Nogueira M, Torres T. https://doi.org/10.7573/dic.212594. Published by Drugs in Context under Creative 
Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in 
the manner specified below. No commercial use without permission. 
Correct attribution: Copyright © 2019 Nogueira M, Torres T. Published by Drugs in Context under Creative Commons License Deed CC BY NC 
ND 4.0. 
Article URL: https://www.drugsincontext.com/guselkumab-for-the-treatment-of-psoriasis-evidence-to-date/
Correspondence: Tiago Torres, Department of Dermatology, Centro Hospitalar do Porto, Porto, Portugal. torres.tiago@outlook.com
Provenance: invited; externally peer reviewed.
Submitted: 16 April 2019; Peer review comments to author: 6 June 2019; Revised manuscript received: 6 June 2019; Accepted: 6 June 2019; 
Publication date: 9 July 2019.
Drugs in Context is published by BioExcel Publishing Ltd. Registered office: Plaza Building, Lee High Road, London, England, SE13 5PT.
Nogueira M, Torres T. Guselkumab for the treatment of psoriasis – evidence to date. Drugs in Context 2019; 8: 212594. DOI: 10.7573/dic.212594 9 of 11
ISSN: 1740-4398
REVIEW – Guselkumab for the treatment of psoriasis drugsincontext.com
References
1.  Di Meglio P, Villanova F, Nestle FO. Psoriasis. Cold Spring Harb Perspect Med. 2014;4(8):1–30.  
https://doi.org/10.1101/cshperspect.a015354
2.  Griffiths CEM, van der Walt JM, Ashcroft DM, et al. The global state of psoriasis disease epidemiology: a workshop report.  
Br J Dermatol. 2017;177(1):e4–e7. https://doi.org/10.1111/bjd.15610
3.  International Federation of Psoriasis Associations. World Psoriasis Day 2015. https://ifpa-pso.com/our-actions/world-psoriasis-day. 
Accessed 7 April 2019.
4.  Rapp SR, Feldman SR, Exum ML, Fleischer ABJ, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. 
J Am Acad Dermatol. 1999;41(3 Pt 1):401–407. https://doi.org/10.1016/S0190-9622(99)70112-X
5.  Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Patients with severe psoriasis are at increased risk of 
cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J. 2010;31(8):1000–1006.  
https://doi.org/10.1093/eurheartj/ehp567
6.  Jindal S, Jindal N. Psoriasis and cardiovascular diseases: a literature review to determine the causal relationship. Cureus. 
2018;10(2):e2195. https://doi.org/10.7759/cureus.2195
7.  Fu Y, Lee C-H, Chi C-C. Association of psoriasis with inflammatory bowel disease: a systematic review and meta-analysis. JAMA 
Dermatol. 2018;154(12):1417–1423. https://doi.org/10.1001/jamadermatol.2018.3631
8.  Kurd SK, Troxel AB, Crits-Christoph P, Gelfand JM. The risk of depression, anxiety, and suicidality in patients with psoriasis: a 
population-based cohort study. Arch Dermatol. 2010;146(8):891–895. https://doi.org/10.1001/archdermatol.2010.186
9.  Koo J, Marangell LB, Nakamura M, et al. Depression and suicidality in psoriasis: review of the literature including the cytokine 
theory of depression. J Eur Acad Dermatol Venereol. 2017;31(12):1999–2009. https://doi.org/10.1111/jdv.14460
10.  Sulzberger M, Witten V. The effect of topically applied compound F in selected dermatoses. J Invest Dermatol. 1952;19(2):101–102
11.  Mueller W, Hermann B. Cyclosporin A for psoriasis. N Engl J Med. 1979;301(10):555. https://doi.org/10.1056/NEJM197909063011015
12.  Winterfield LS, Menter A, Gordon K, Gottlieb A. Psoriasis treatment: current and emerging directed therapies. Ann Rheum Dis. 
2005;64(Suppl. 2):87–90. https://doi.org/10.1136/ard.2004.032276
13.  Torres T. Selective interleukin-23 p19 inhibition: another game changer in psoriasis? Focus on risankizumab. Drugs. 
2017;77(14):1493–1503. https://doi.org/10.1007/s40265-017-0794-1
14.  Chan TC, Hawkes JE, Krueger JG. Interleukin 23 in the skin: role in psoriasis pathogenesis and selective interleukin 23 blockade as 
treatment. Ther Adv Chronic Dis. 2018;9(5):111–119. https://doi.org/10.1177/2040622318759282
15.  Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin 
Immunol. 2017;140(3):645–653. https://doi.org/10.1016/j.jaci.2017.07.004
16.  Kim J, Krueger JG. The immunopathogenesis of psoriasis. Dermatol Clin. 2015;33(1):13–23.  
https://doi.org/10.1016/j.det.2014.09.002
17.  Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 cells. Annu Rev Immunol. 2009;27(1):485–517.  
https://doi.org/10.1146/annurev.immunol.021908.132710
18.  Res PCM, Piskin G, de Boer OJ, et al. Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their 
involvement in the pathogenesis of psoriasis. PLoS One. 2010;5(11):e14108. https://doi.org/10.1371/journal.pone.0014108
19.  Zaba LC, Krueger JG, Lowes MA. Resident and “inflammatory” dendritic cells in human skin. J Invest Dermatol. 2009;129(2):302–
308. https://doi.org/10.1038/jid.2008.225
20.  Hawkes JE, Yan BY, Chan TC, Krueger JG. Discovery of the IL-23/IL-17 signaling pathway and the treatment of psoriasis. J Immunol. 
2018;201(6):1605–1613. https://doi.org/10.4049/jimmunol.1800013
21.  Di Cesare A, Di Meglio P, Nestle FO. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol. 
2009;129(6):1339–1350. https://doi.org/10.1038/jid.2009.59
22.  Yoon J, Leyva-Castillo JM, Wang G, et al. IL-23 induced in keratinocytes by endogenous TLR4 ligands polarizes dendritic cells to 
drive IL-22 responses to skin immunization. J Exp Med. 2016;213(10):2147–2166. https://doi.org/10.1084/jem.20150376
23.  Fragoulis GE, Siebert S, McInnes IB. Therapeutic targeting of IL-17 and IL-23 cytokines in immune-mediated diseases. Annu Rev 
Med. 2016;67(1):337–353. https://doi.org/10.1146/annurev-med-051914-021944
24.  Gordon KB, Blauvelt A, Papp KA, et al. Phase 3 trials of Ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 
2016;375(4):345–356. https://doi.org/10.1056/NEJMoa1512711
BioExcel Publishing Limited is registered in England Number 10038393. VAT GB 252 7720 07.
For all manuscript and submissions enquiries, contact the Editor-in-Chief gordon.mallarkey@bioexcelpublishing.com
For all permissions, rights and reprints, contact David Hughes david.hughes@bioexcelpublishing.com
Nogueira M, Torres T. Guselkumab for the treatment of psoriasis – evidence to date. Drugs in Context 2019; 8: 212594. DOI: 10.7573/dic.212594 10 of 11
ISSN: 1740-4398
REVIEW – Guselkumab for the treatment of psoriasis drugsincontext.com
25.  Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis – results of two phase 3 trials. N Engl J Med. 
2014;371(4):326–338. https://doi.org/10.1056/NEJMoa1314258
26.  Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 
2015;373(14):1318–1328. https://doi.org/10.1056/NEJMoa1503824
27.  Papp KA, Reich K, Paul C, et al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in 
patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016;175(2):273–286. https://doi.org/10.1111/bjd.14493
28.  Reich K, Pinter A, Lacour JP, et al. Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results 
from IXORA-S, a phase III study. Br J Dermatol. 2017;177(4):1014–1023. https://doi.org/10.1111/bjd.15666
29.  Thaçi D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe 
plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73(3):400–409.  
https://doi.org/10.1016/j.jaad.2015.05.013
30.  Griffiths CEM, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis 
(UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541–551.  
https://doi.org/10.1016/S0140-6736(15)60125-8
31.  Papp K, Leonardi C, Menter A, et al. Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment. J Am Acad 
Dermatol. 2014;71(6):1183–1190.e3. https://doi.org/10.1016/j.jaad.2014.08.039
32.  Sofen H, Smith S, Matheson RT, et al. Guselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in 
patients with moderate-to-severe psoriasis. J Allergy Clin Immunol. 2014;133(4):1032–1040. https://doi.org/10.1016/j.jaci.2014.01.025
33.  Gordon KB, Duffin KC, Bissonnette R, et al. A phase 2 trial of guselkumab versus adalimumab for plaque psoriasis. N Engl J Med. 
2015;373(2):136–144. https://doi.org/10.1056/NEJMoa1501646
34.  Blauvelt A, Papp KA, Griffiths CEM, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, 
compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase 
III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405–417.  
https://doi.org/10.1016/j.jaad.2016.11.041
35.  Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared 
with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: 
results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 
2017;76(3):418–431. https://doi.org/10.1016/j.jaad.2016.11.042
36.  Langley RG, Tsai T-F, Flavin S, et al. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response 
to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial. Br J Dermatol. 2018;178(1):114–123.  
https://doi.org/10.1111/bjd.15750
37.  Zhuang Y, Calderon C, Marciniak SJ, et al. First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety  
in healthy subjects and patients with moderate-to-severe psoriasis. Eur J Clin Pharmacol. 2016;72(11):1303–1310.  
https://doi.org/10.1007/s00228-016-2110-5
38.  Langley R. Guselkumab demonstrates superior long-term responses to secukinumab at Week48 in the treatment of moderate to 
severe psoriasis: results from the ECLIPSE trial. In: 3rd Inflammatory Skin Disease Summit. Vienna, Austria; 2018.
39.  Frampton JE. Tildrakizumab: a review in moderate-to-severe plaque psoriasis. Am J Clin Dermatol. March 2019.  
https://doi.org/10.1007/s40257-019-00435-9
40.  Haugh IM, Preston AK, Kivelevitch DN, Menter AM. Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis. Drug Des 
Devel Ther. 2018;12:3879–3883. https://doi.org/10.2147/DDDT.S167149
41.  Markham A. Guselkumab: first global approval. Drugs. 2017;77(13):1487–1492. https://doi.org/10.1007/s40265-017-0800-7
42.  Ault A. Guselkumab (Tremfya) gets CHMP backing for plaque psoriasis. https://www.medscape.com/viewarticle/885745. 
Published 2017. Accessed 26 February  2019.
43.  European Medicines Agency. Tremfya 100 mg: product information and public assessment report.  
https://www.ema.europa.eu/en/medicines/human/EPAR/tremfya. Published 2017. Accessed 1 March 2019.
44.  Yao Z, Hu C, Zhu Y, et al. Population Pharmacokinetic modeling of guselkumab, a human IgG1λ monoclonal antibody targeting 
IL-23, in patients with moderate to severe plaque psoriasis. J Clin Pharmacol. 2018;58(5):613–627. https://doi.org/10.1002/jcph.1063
45.  Smolen JS, Agarwal SK, Ilivanova E, et al. A randomised phase II study evaluating the efficacy and safety of subcutaneously 
administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate. 
Ann Rheum Dis. 2017;76(5):831–839. https://doi.org/10.1136/annrheumdis-2016-209831
46.  Ohtsuki M, Kubo H, Morishima H, Goto R, Zheng R, Nakagawa H. Guselkumab, an anti-interleukin-23 monoclonal antibody, 
for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: efficacy and safety results from a phase 3, 
randomized, double-blind, placebo-controlled study. J Dermatol. 2018;45(9):1053–1062. https://doi.org/10.1111/1346-8138.14504
47.  Griffiths CEM, Papp KA, Kimball AB, et al. Long-term efficacy of guselkumab for the treatment of moderate-to-severe psoriasis: 
results from the phase 3 VOYAGE 1 trial through two years. J Drugs Dermatol. 2018;17(8):826–832. 
Nogueira M, Torres T. Guselkumab for the treatment of psoriasis – evidence to date. Drugs in Context 2019; 8: 212594. DOI: 10.7573/dic.212594 11 of 11
ISSN: 1740-4398
REVIEW – Guselkumab for the treatment of psoriasis drugsincontext.com
48.  Gordon KB, Blauvelt A, Foley P, et al. Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque 
psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies. Br J Dermatol. 2018;178(1):132–139.  
https://doi.org/10.1111/bjd.16008
49.  Reich K, Papp KA, Armstrong AW, et al. Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 
weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies. Br J Dermatol. 2019;180(5):1039–1049. 
https://doi.org/10.1111/bjd.17454
50.  Sano S, Kubo H, Morishima H, Goto R, Zheng R, Nakagawa H. Guselkumab, a human interleukin-23 monoclonal antibody in 
Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: efficacy and safety analyses of a 52-week, 
phase 3, multicenter, open-label study. J Dermatol. 2018;45(5):529–539. https://doi.org/10.1111/1346-8138.14294
51.  Deodhar A, Gottlieb AB, Boehncke WH, et al. Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a 
randomised, double-blind, placebo-controlled, phase 2 study. Lancet. 2018;391(10136):2213–2224.  
https://doi.org/10.1016/S0140-6736(18)30952-8
52.  Deepak P, Sandborn WJ. Ustekinumab and anti-interleukin-23 agents in Crohn’s disease. Gastroenterol Clin North Am. 
2017;46(3):603–626. https://doi.org/10.1016/j.gtc.2017.05.013
53.  Verstockt B, Deleenheer B, Van Assche G, Vermeire S, Ferrante M. A safety assessment of biological therapies targeting the IL-23/
IL-17 axis in inflammatory bowel diseases. Expert Opin Drug Saf. 2017;16(7):809–821.  
https://doi.org/10.1080/14740338.2017.1338273
54.  Papp KA, Griffiths CEM, Gordon K, et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final 
results from 5 years of follow-up. Br J Dermatol. 2013;168(4):844–854. https://doi.org/10.1111/bjd.12214
55.  Liu J, Cao S, Kim S, et al. Interleukin-12: an update on its immunological activities, signaling and regulation of gene expression. 
Curr Immunol Rev. 2005;1(2):119–137. 
56.  Kleinschek MA, Muller U, Brodie SJ, et al. IL-23 enhances the inflammatory cell response in Cryptococcus neoformans infection 
and induces a cytokine pattern distinct from IL-12. J Immunol. 2006;176(2):1098–1106. 
57.  Langowski JL, Zhang X, Wu L, et al. IL-23 promotes tumour incidence and growth. Nature. 2006;442(7101):461–465.  
https://doi.org/10.1038/nature04808
58.  Kulig P, Musiol S, Freiberger SN, et al. IL-12 protects from psoriasiform skin inflammation. Nat Commun. 2016;7(1):13466.  
https://doi.org/10.1038/ncomms13466
59.  Gagliani N, Vesely MCA, Iseppon A, et al. Th17 cells transdifferentiate into regulatory T cells during resolution of inflammation. 
Nature. 2015;523(7559):221–225. https://doi.org/10.1038/nature14452
60.  Al-Salama ZT, Scott LJ. Guselkumab: a review in moderate to severe plaque psoriasis. Am J Clin Dermatol. 2018;19(6):907–918. 
https://doi.org/10.1007/s40257-018-0406-1
61.  Machado A, Torres T. Guselkumab for the treatment of psoriasis. BioDrugs. 2018;32(2):119–128.  
https://doi.org/10.1007/s40259-018-0265-6
62.  Yang EJ, Sanchez IM, Beck K, Sekhon S, Wu JJ, Bhutani T. Guselkumab for the treatment of moderate-to-severe plaque psoriasis. 
Expert Rev Clin Pharmacol. 2018;11(4):333–344. https://doi.org/10.1080/17512433.2018.1445967
63.  Galluzzo M, D’Adamio S, Campione E, Bianchi L, Talamonti M. A safety evaluation of guselkumab for the treatment of psoriasis. 
Expert Opin Drug Saf. 2018;17(7):741–751. https://doi.org/10.1080/14740338.2018.1488963
